Trade Report: The Buckingham Asset Management LLC Sold shares of Celgene Corp. (CELG)

The Buckingham Asset Management LLC Sold shares of Celgene Corp. (CELG)

Buckingham Asset Management LLC decreased its stake in Celgene Corp. (NASDAQ:CELG) by 40.1% during the second quarter, Holdings Channel reports. The institutional investor owned 2,685 shares of the biopharmaceutical company’s stock after selling 1,797 shares during the period. Buckingham Asset Management LLC’s holdings in Celgene Corp. were worth $265,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in CELG. Pictet Asset Management Ltd. raised its position in shares of Celgene Corp. by 1.5% in the first quarter. Pictet Asset Management Ltd. now owns 1,009,775 shares of the biopharmaceutical company’s stock worth $101,816,000 after buying an additional 15,199 shares during the last quarter. Baker Avenue Asset Management LP purchased a new position in shares of Celgene Corp. during the first quarter worth approximately $360,000. Simonbaker & Partners LLC purchased a new position in shares of Celgene Corp. during the first quarter worth approximately $311,000. Marshall & Sullivan Inc. WA raised its position in shares of Celgene Corp. by 2.6% in the first quarter. Marshall & Sullivan Inc. WA now owns 15,662 shares of the biopharmaceutical company’s stock worth $1,567,000 after buying an additional 395 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Celgene Corp. by 5.3% in the first quarter. Geode Capital Management LLC now owns 6,931,718 shares of the biopharmaceutical company’s stock worth $692,509,000 after buying an additional 348,123 shares during the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Shares of Celgene Corp. (NASDAQ:CELG) traded down 0.78% during mid-day trading on Friday, reaching $103.90. The company’s stock had a trading volume of 6,962,527 shares. The stock has a market capitalization of $80543.59 billion, a price-to-earnings ratio of 39.51 and a beta of 1.49. The company’s 50-day moving average is $103.87 and its 200-day moving average is $105.29. Celgene Corp. has a 52 week low of $93.05 and a 52 week high of $127.97.

Celgene Corp. (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.48 by $0.10. Celgene Corp. had a return on equity of 70.92% and a net margin of 19.71%. The business had revenue of $2.98 billion for the quarter, compared to analyst estimates of $2.84 billion. During the same quarter in the prior year, the company earned $1.23 earnings per share. The company’s revenue was up 27.8% on a year-over-year basis. Equities analysts predict that Celgene Corp. will post $5.86 EPS for the current year.

CELG has been the subject of several analyst reports. Canaccord Genuity reaffirmed a “buy” rating and issued a $156.00 price objective on shares of Celgene Corp. in a research note on Tuesday, July 5th. Leerink Swann reaffirmed a “hold” rating and issued a $125.00 price objective on shares of Celgene Corp. in a research note on Tuesday, July 5th. JMP Securities reaffirmed a “buy” rating and issued a $152.00 price objective on shares of Celgene Corp. in a research note on Wednesday, July 6th. Vetr lowered Celgene Corp. from a “buy” rating to a “hold” rating and set a $106.06 price objective for the company. in a research note on Wednesday, July 6th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $138.00 price objective on shares of Celgene Corp. in a research note on Sunday, July 10th. Three equities research analysts have rated the stock with a hold rating and twenty-five have given a buy rating to the company’s stock. Celgene Corp. has an average rating of “Buy” and a consensus target price of $136.29.

In other news, major shareholder Corp /De/ Celgene acquired 800,150 shares of the company’s stock in a transaction on Monday, October 24th. The shares were bought at an average price of $14.00 per share, with a total value of $11,202,100.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael A. Friedman sold 56,116 shares of the firm’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $103.66, for a total value of $5,816,984.56. Following the transaction, the director now directly owns 50,000 shares in the company, valued at approximately $5,183,000. The disclosure for this sale can be found here. Insiders own 0.97% of the company’s stock.

About Celgene Corp.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Related posts

Leave a Comment